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1. Introduction 
Prostate cancer is one of the most frequently diagnosed malignancies among the male 
population and the second common cancer-related death worldwide after lung cancer 
(Jemal et al., 2010). It is estimated that 30% of male older than 50 years are harboring 
microscopic transformation of adenocarcinoma within the prostate gland. Because of the 
dramatic rise in the incidence of prostate cancer with the rate increasing approximately 6% 
per year worldwide (Eschenbach, 1996), the study of precursor lesions of prostate cancer is 
emerging concept in the field of prostate cancer prevention. 
2. Prostatic intraepithelial neoplasia 
John McNeal introduced the term intraductal dysplasia of the prostate in the early 1960s, 
postulating that carcinoma of the prostate arose from active ductal/acinar epithelium and 
not from atrophic acini (McNeal, 1965, 1988; Amin et al., 1993). Later various terms have 
been rasied such as large acinar atypical hyperplasia with malignant change (Allam et al., 1996) 
and ductacinar dysplasia (McNeal, 1988). None of these have gained popularity. The term 
Prostatic intraepithelial neoplasia (PIN) was first proposed by Bostwick and Brawer in 1987, 
and this term was accepted at the 1989 Workshop on Prostatic Dysplasia (Bethesda, Md; 
March 1989) as the preferred nomenclature for this preneoplastic change (Bethesda, Md; 
March 1989; Drago et al., 1989). PIN refers to the putative precancerous end of the 
continuum of cellular proliferations within the lining of prostatic ducts, ductules and acini 
(Bostwick and Amin, 1996; Bostwick and Qian, 2004).  
PIN is the most likely precursor of prostate cancer and has been described as a premalignant 
or pre-invasive form of prostate cancer (Sakr et al., 1993; Bostwick, 1996). Although two 
histopathologic lesions in the prostate were proposed as being premalignant (PIN and 
atypical adenomatous hyperplasia, AAH), there is less evidence of a premalignant role for 
AAH than there is for PIN (De La Torre et al., 1993; Jones and Young, 1994; Epstein, 1994; 
Bostwick, 1996). Within these lesions, studies have identified impaired and abnormal 
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differentiation, increased proliferation, and abnormal DNA content and elevated ras 
protooncogene mRNA expression (Jones and Young, 1994). There are two grades of PIN 
(low-grade and high-grade), although the term PIN is usually used to indicate high-grade 
PIN (HGPIN). The high level of interobserver variability with low-grade PIN (LGPIN) limits 
its clinical utility, and many pathologists do not report this finding except in research 
studies. Low grade PIN (LGPIN) is only a very early precursor, and might even not be 
considered as a precancerous lesion. Moreover, the distinction between LGPIN and normal 
epithelium might be observer related (Lipski et al., 1996; Zlotta and Schulman, 1999; Vis and 
Van der Kwast, 2001). 
PIN lesions can only be diagnosed by histopathological examination of prostatic tissue. It is 
impossible to detect PIN clinically by digital rectal examination (DRE), prostate specific 
antigen (PSA) or ultrasound. Cytologically, LGPIN and HGPIN have clear and reproducible 
features (Table 1). Histologically, however, different architectural variations exist for 
HGPIN (Fig. 1). At least four distinct patterns can be distinguished: flat, tufting, 
micropapillary and cribriform (Bostwick, 1989). Less frequent are signet cell pattern, small 
cell neuroendocrine pattern, mucinous pattern and microvacuolar pattern. In the big 
majority of PIN-lesions, a tufting pattern can be found. Frequently, multiple patterns can be 
found at the same time.  
 
Structural 
pattern 
Low grade PIN (LGPIN) High grade PIN (HGPIN) 
Architecture Crowding, stratification, 
irregular spacing 
More changes, 4 patterns (T, MP, 
cribriform, flat)* 
Nuclei 
Chromatin 
Nucleoli 
Slight enlargement, size 
variation  
Normal 
Rarely prominent 
Definite enlargement, less size 
variation 
Increased density and clumping 
Frequently prominent 
Basal cell layer Intact May show some disruption 
Basement 
membrane 
Intact Intact 
* T indicates tufting; MP- micropapillary. 
Table 1.  Prostatic intraepithelial neoplasia (PIN): diagnostic criteria modified from Bostwick  
and Brawer (1987) 
HGPIN is the most significant risk factor for prostate cancer in needle biopsy specimens. Its 
role as the preinvasive stage of cancer was recently confirmed conclusively in two separate 
mouse models (Kasper et al., 1998; Garabedian et al., 1998).  PIN coexists with cancer in more 
than 85% of cases (McNeal and Bostwick, 1986; Qian et al., 1997) but retains an intact or 
fragmented basal cell layer, unlike cancer, which lacks a basal cell layer (Bostwick and 
Brawer, 1987). PIN is strongly predictive of adenocarcinoma, and its identification in biopsy 
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specimens of the prostate warrants further search for concurrent cancer. PIN alone has no 
apparent influence on serum PSA concentration, and it is not apparently visible by current 
imaging techniques. 
 
Fig. 1. Prostatic intraepithelial neoplasia Histology. (a). Multiple dysplastic and 
hyperplastic sites were seen within the same glandular epithelium (×200 magnifications; 
H&E) (b). Fully developed PIN with loss of basal epithelial cells (×200 magnifications; H&E) 
(Arunkumar et al., 2006). Architectural pattern of high grade prostatic intraepithelial 
neoplasia (PIN) such as tufting (c), cribriform (d), and micropapillary (e) structures were 
observed (×200 magnifications; H&E) (f). The cell number in PIN was markedly increased, 
and cell density with sparse cytoplasm (arrow headed) (×400 magnifications; H&E) 
(Banudevi et al., 2011a & b). E- Epithelium; L- Lumen; S-Stroma 
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3. Identification of PIN: Histological criteria 
The classification of PIN into low grade and high grade is based mainly on the cytological 
characteristics of the cells. The nuclei of cells composing LGPIN are enlarged, vary in size, 
have normal or slightly increased chromatin content, and possess small or inconspicuous 
nucleoli (Figs. 2 and 3). HGPIN is characterised by cells with large nuclei of relatively 
uniform size, an increased chromatin content, which might be irregularly distributed, and 
prominent nucleoli that are similar to those of carcinoma cells (Fig. 4). The basal cell layer is 
intact or rarely interrupted in LGPIN, but may have frequent disruptions in high grade 
lesions. Although the cytological features of LGPIN and HGPIN are fairly constant, the 
architecture shows a spectrum, varying from a flattened epithelium to a florid cribriform 
proliferation. Four basic patterns that often coexist have been described by Bostwick and 
colleagues (Bostwick et al., 1993): flat, tufting, micropapillary, and cribriform. Familiarity 
with this diverse architectural spectrum may facilitate the histological recognition of PIN, 
even though these various architectural patterns have no apparent clinicopathological 
relevance (Bostwic et al., 1993). 
Neuroendocrine differentiation occurs in PIN, where it is intermediate in degree between 
normal prostate (which has the most cells with neuroendocrine differentiation) and 
carcinoma (Bostwick et al., 1994a; Di Sante Agnese, 1996). Paneth cell like change of the 
prostatic epithelium (neuroendocrine cells with large eosinophilic granules) is considered to 
be a distinct form of neuroendocrine differentiation characterised by isolated cells or small 
groups of cells with prominent eosinophilic cytoplasmic granules. 
 
 
  
Fig. 2. Normal prostate. The duct is lined by a two cell layer– for example, the basal cell and 
the secretory or luminal cell layers. 
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Fig. 3. Low grade prostatic intraepithelial neoplasia. The nuclei of the secretory cells are 
enlarged, vary in size, have normal or slightly increased chromatin content, and possess 
small or inconspicuous nucleoli. The basal cell layer is almost intact. 
 
 
Fig. 4. High grade prostatic intraepithelial neoplasia with cribriform patterns. The 
perimeter cells show features of clearly dysplastic cells, whereas, going from the periphery 
towards the centre, the nuclei become smaller and the nucleoi become less apparent 
(“maturation phenomenon”). The basal cell layer is disrupted.  
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4. PIN incidence 
The incidence of PIN varies according to the male population. The lowest likelihood is in 
men participating in PSA screening and early detection studies, with an incidence of PIN in 
biopsies ranging from 0.7% to 20% (Bostwick et al., 1996; Langer et al., 1996; Wills et al., 1997; 
Skjorten et al., 1997). Men seen by urologists in practice have PIN in 4.4% to 25% of 
contemporary 18-gauge needle biopsies obtained by urologists. Those undergoing 
transurethral resections have the highest likelihood of PIN, varying from 2.8% to 33% 
(Pacelli et al., 1997). In such cases, all tissues should be examined, but serial sections of 
suspicious foci are probably not usually necessary. Select anti-keratin antibodies such as 
34ǃ-E12 (high molecular weight keratin) may be used to stain tissue sections for the 
presence of basal cells, recognizing that PIN retains intact or fragmented basal cell layer, 
whereas cancer does not (Bostwick and Brawer, 1987). By immunohistochemical analysis, 
Prostate tumor overexpressed-1 (PTOV1) was considered as good marker for PIN which 
shows strong immunoreactivity in areas of carcinoma and HGPIN (Morote et al., 2008) 
5. PIN distribution 
Prostatic intraepithelial neoplasia is found predominantly in the peripheral zone of the 
prostate (75%–80%), rarely in the transition zone (10%–15%), and extremely rarely in the 
central zone (< 5%). This distribution parallels the frequency of the zonal predilection for 
prostatic carcinoma (Bostwick et al., 1995; Gaudin et al., 1997,; Pacelli et al., 1997). The 
frequency of HGPIN in needle biopsy series ranges from 5% to 16% and in transurethral 
resection of the prostate specimens between 2.3% and 4.2% (Bostwick et al., 1995; Gaudin et 
al., 1997; Melissari et al., 2006) McNeal in 1969 mentioned the multifocality of this process 
(McNeal, 1969; 1988); this observation has since been corroborated by others. 
6. Immunohistochemistry in PIN 
Numerous studies to highlight the basal cells and the secretory cells have been done 
(Brawer et al., 1985; McNeal et al., 1988a, 1988b; Perlman and Epstein, 1990; Abhrams et al., 
2002; Zhou et al., 2003; Wu et al., 2004). The basal cells and luminal cells of the prostatic 
glands display different keratin immunoreactivity. The high-molecular-weight 
cytokeratin monoclonal antibody (clone 34ǃE12, also referred to as CK903) recognizes 
keratin proteins of 49, 51, 57, and 66 kD and labels the basal cells but not the 
luminal/secretory cells of the prostatic glands that stain with prostate-specific antigen 
and prostatic acid phosphatase. ǂ-Methylacyl CoA-racemase (AMACR) stains the cells of 
adenocarcinoma but usually does not stain benign prostate glands (Brawer et al., 1985; 
McNeal et al., 1988a, 1988b; Perlman and Epstein, 1990; Abhrams et al., 2002; Zhou et al., 
2003; Wu et al., 2004).  
Other antibodies that also mark basal cells include p63 (McNeal, 1969) and CK5/6 (Abhrams 
et al., 2002). p63 is a nuclear stain, whereas CK5/6 stains the cytoplasm (Abhrams et al., 2002; 
Zhou et al., 2003). The basal cell layer is present in benign epithelial proliferations, may be 
disrupted in HGPIN, and is absent in invasive carcinoma (Bostwick and Brawer , 1987).  
Bostwick and Brawer in 1987 have shown that the frequency and extent of basal cell 
disruption in PIN is related to the PIN grade and is greatest in HGPIN. 
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A numerous of Immuno histochemical studies (McNeal et al., 1988a; Perlman and Epstein, 
1990; Deschenes and Weidner, 1990; Nagle et al., 1991; Sesterhenn et al., 1991) have been 
done to correlate the relationship between HGPIN and invasive carcinoma, Including 
evaluation of monoclonal antikeratin antibody, KA4, Ulex europaeus lectin (UEA-l), lectin 
binding pattern, and vimentin. Wu et al. demonstrated that a significantly higher P504S 
(AMACR) positive rate (56.0%) was found in isolated HGPIN glands adjacent to cancer 
(distance less than 5 mm) compared with those away from cancer (distance more than 5 
mm; 14%, P < 0.001) (Wu et al., 2004). High-grade PIN glands adjacent to cancer also showed 
a higher (P <0 .001) P504S intensity than did those away from cancer. 
Other studies including argyrophilic nucleolar organizer regions and static DNA flow 
cytometry suggest that HGPIN and carcinoma have similar proliferative activity and DNA 
content, and hence HGPIN is the most likely precursor of cancer (Sesterhenn et al., 1991; 
Weinberg and Weidner, 1993; Amin et al., 1994). Cytogenetic abnormalities (involving 7q, 
8q, 10q, 16q) and numerical chromosomal changes are noted in HGPIN and carcinoma 
(Emmert-Buck et al., 1995; Macoska et al., 1995; Qian et al., 1999; Al-Maghrabi et al., 2002). 
High-grade PIN and prostate cancer share genetic and molecular markers as well, with PIN 
representing an intermediate stage between benign epithelium and invasive carcinoma 
(Brawer, 2005). 
PIN offers promise as an intermediate endpoint in studies of chemoprevention of prostatic 
carcinoma (Bostwick et al., 1994b; Aquilina et al., 1997). Recognizing the slow growth rate of 
prostate cancer and the considerable amount of time needed in animal and human studies 
for adequate follow-up, the non-invasive precursor lesion PIN is a suitable intermediate 
histologic marker to indicate subsequent likelihood of cancer (Aquilina et al., 1997). 
7. Chemoprevention strategies 
Chemoprevention is the administration of agents to prevent induction of cancer, or to 
inhibit or delay its progression. In prostatic neoplasia, the time from tumour initiation and 
progression to invasive carcinoma often begins in men in the fourth and fifth decades of life 
and extends across decades. This phenomenon represents a unique opportunity to arrest or 
reverse the process of carcinogenesis with the use of chemopreventive agents. Animal 
models in defining efficacy of chemoprevention agents against prostate cancer. Detection of 
inhibitory effects on de novo prostate cancer development requires a high cancer incidence 
and similarity of induced tumors to human prostate carcinomas. The following animal 
models have produced high incidences of multifocal prostate adenocarcinoma: transgenic 
mice with oncogenes expressed in a prostate specific fashion; Noble rats that have been 
treated chronically with combination of 17ǃ-estradiol and testosterone; and Wistar or F344 
rats treated sequentially with a single injection of N-methyl-N-nitrosourea (MNU) and 
chronic administration of testosterone. 
PIN most often occurs in the first two models, and metastases are frequent in some 
transgenic models and the MNU-testosterone model (Shirai et al., 1991; Pollard et al., 1992; 
Kadomatsu et al., 1993; Slayter et al., 1994; Ingles et al., 1997). The chemopreventive efficacy 
of a series of agents using a model in which hormone dependent prostate cancer is induced 
in the Wistar-Unilever rat (McCormick, 1998). This is achieved by sequential treatment with 
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an antiandrogen (cyproterone acetate), and androgen (testosterone propionate) and a direct 
acting chemical carcinogen (N-methyl-N-nitrosourea), followed by chronic androgen 
stimulation (testosterone). This regimen reproducibly induces a high incidence (< 75%) of 
prostate cancer, with no gross toxicity and a low incidence of neoplasia in the seminal 
vesicles and other non-target tissue. 
Dehydroepiandrosterone (DHEA) and 9-cis-retinoic acid (9-cis-RA) are the most active 
chemopreventive agents identified to date. DHEA inhibits the induction of prostate cancer 
when administration is started before carcinogen exposure, and when it is delayed until 
incipient neoplastic lesions are present. Chronic administration of 9-cis-RA starting before 
carcinogen exposure is highly effective in the chemoprevention of prostate cancer. Liarozole 
fumarate confers modest protection against induction of prostate cancer, whereas N-(4-
hydroxyphenyl) retinamide (4-HPR), a-difluoromethylornithine, DL-ǂ-tocopherol acetate 
(vitamin E), oltipraz, and L-selenomethionine are inactive. The differential activity of 9-cis-RA 
and 4-HPR suggests the ligand specificity may be a determinant of retinoid action in prostate 
cancer chemoprevention. Chemoprevention of MNU +T induced prostate carcinogenesis at 
low dose level (0.5 μg/kg body weight) of calcitriol has significant potency to inhibit prostatic 
hyperplasia, dysplasia and PIN, and also decreased serum PAcP activity. Calcitriol may be an 
effective therapy for the treatment of early prostate cancer (Senthil kumar et al., 2006).  
Christov et al. (2002) studied that PIN can be used for assessing the efficacy of 
chemopreventive agents on prostate carcinogenesis. Dially disulfide, an organosulfur 
compound of garlic, has significant potency as an inhibitor of cancer induction in Sprague 
Dawley rat prostate by inhibiting PIN, hyperplastic and dysplastic foci (Arunkumar et al., 
2006). Zinc also acts as a chemopreventive agent against prostate cancer by inducing 
regression in PIN (Banudevi et al., 2011a). Zinc inhibits PIN an early stage of prostate cancer. 
This study proves the ability of zinc to restore the PIN changes particularly in the rat ventral 
prostate induced by carcinogen and testosterone thereby indicating its anticarcinogenic 
potential (Banudevi et al., 2011a). As the dorsolateral prostate is most likely homologue to 
the human prostate (Bosland et al., 1990), in our recent study we proved that zinc was found 
to inhibit the growth and decrease dorsolateral prostatic acid phosphatase, zinc, citrate 
levels, phase I drug metabolizing enzyme activities, lipid peroxide, H2O levels, proliferating 
cell nuclear antigen (PCNA), Bcl2, Bcl-XL expressions with concomitant increase in phase II 
enzyme activities, GSH levels, p53, Bax, caspase-3 expressions in MNU testosterone induced 
model of prostate carcinogenesis (Banudevi et al., 2011b). Signs of dysplasia, a characteristic 
of prostatic intraepithelial neoplasia, were evident in the dorsolateral prostatic 
histoarchitecture. Thus, zinc may act as an essential trace element against MNU and 
testosterone induced prostatic preneoplastic progression in Sprague Dawley rats. 
The most efficient strategy for developing a chemoprevention programme is to perform two 
clinical trials concurrently, each based on the modulation of high grade PIN but in different 
target populations (Nelson et al., 1996; Bostwick, 1997). In patients with high grade PIN 
associated with prostate cancer, a prospective, double blind, placebo controlled chemoactive 
pilot study designed to measure the response of a potential chemopreventive agent in the 
period (three to six weeks) before radical prostatectomy could easily be performed.  
Androgen deprivation treatment is commonly used in this population to downsize the 
prostate before radical prostatectomy. This study may provide information regarding the 
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effectiveness of proposed agents on surrogate endpoint biomarkers, premalignant lesions, 
and cancer. In particular, such an investigation would determine the response of PIN to the 
agent in whole mounted radical prostatectomy specimens. In some preliminary 
investigations it has been shown that there is a marked decrease in the prevalence and 
extent of PIN in prostates after androgen deprivation treatment, as compared with 
untreated prostates (Ferguson et al., 1994). This is accompanied by regressive changes in the 
secretory epithelium. Apoptotic bodies are more often seen in the treated normal prostate, 
PIN, and prostate cancer than in untreated cases. This suggests that androgen ablation 
induces epithelial regression by enhancing apoptosis. The low proliferating cell nuclear 
antigen (PCNA) and Ki67 related values and the absence of mitoses in PIN as well as in 
normal prostate and prostate cancer in the treated cases indicates suppressed proliferation 
activity as a consequence of androgen deprivation treatment (Armas et al., 1993; Montironi et 
al., 1994). It has been reported that angiogenesis is inhibited in prostate lesions when total 
androgen ablation induces cell regression and activation of the apoptosis (Montironi et al., 
1996). Consequently, the epithelial cells are blocked from expressing, producing, or 
exporting angiogenic molecules. All these findings indicate that the dysplastic prostatic 
epithelium is hormone dependent. 
A short term prospective, double blind, placed controlled phase II chemopreventive trial 
with cancer as an endpoint could be done in patients with high grade PIN without cancer.  
Chemoprevention trials designed to reverse high grade PIN may be confounded by the 
presence of underlying but undetected addressed by requiring a second biopsy with 
negative findings for cancer before entry into the study (preferably sextant biopsies with 
special attention to areas of abnormality on ultrasonogram or digital rectal examination), 
and by including enough subjects in the study and control groups to equalise the risk of 
coexistent cancer between the two groups. 
PIN is routinely monitored by repeat biopsy in contemporary urological practice. Periodic 
re-evaluation would be necessary, including physical examination, rebiopsy, and evaluation 
of surrogate intermediate endpoint biomarkers. If subsequent biopsy reveals prostate 
cancer, these patients need definitive treatment. Those with PIN or no malignancy need 
continued observation (Bostwick, 1997). 
8. Clinical chemoprevention studies 
Table 2 reports agents, the treatment periods, and the primary endpoints used in clinical 
chemoprevention studies sponsored or funded by the National Cancer Institute (Kellof, 
1997). 
Green tea catechins 
Epidemiological and case–control studies have garnered support for the chemopreventive 
properties of green tea (Jian et al., 2004). A recent study was conducted on 60 volunteers 
with high-grade prostate intraepithelial neoplasia, a putative precursor of prostate 
adenocarcinoma (Bettuzzi et al., 2006). Patients received green tea compounds in capsule 
form 200 mg three times per day. Following 1 year of treatment, only 3% of patients that 
received the green tea polyphenols were diagnosed with cancer compared with 30% in the 
placebo group. Furthermore, patients that received the green tea capsules exhibited a longer 
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latency to tumor detection and exhibited an improved quality of life. Another phase II 
study, in which 6 g/day of tea was administered to 42 patients with asymptomatic, 
androgen- independent prostate cancer, has demonstrated that a single patient achieved a 
PSA response of >50% that lasted for approximately 1 month. These patients suffered with 
side effects that include diarrhea, nausea and fatigue (Jatoi et al., 2003). Another clinical 
study used 250 mg dose of green tea polyphenols twice daily. In this study, 6 out of 19 
patients had disease control for 3 to 5 months and there was only 1 patient whose PSA rise 
was affected by green tea supplementation. The dose used in this study did not discernibly 
alter the course of hormone-refractory prostate cancer (Choan et al., 2005). These results 
suggest that green tea possesses cancer chemopreventive properties and minimal anti-
neoplastic activity against advance stage prostate cancer. 
 
Table 2. National Cancer Institute Chemoprevention Branch: sponsored od funded phase 
II/III clinical chemoprevention trials: prostate cancer 
Selective estrogen receptor modulators (SERMs) 
Interest in SERMs as preventive agents has been stimulated by an apparent role of estrogens 
in the pathogenesis of prostate cancer, through promotion of cell growth. SERMs are 
generally considered to be ‘weak estrogens’ because they possess both agonist and 
antagonist activities depending on the specific tissue type and on the relative ER subtype 
interactions. Consequently this class of agents has been called selective estrogen receptor 
modulators or SERMs. As with phytoestrogens, SERMs appear to possess the ability to 
suppress prostate carcinogenesis. Toremifene has been evaluated in a phase IIa exploratory 
trial in men with high-grade PIN (Steiner and Pound, 2003). After 4 months of treatment 
with a daily oral dose of toremifene, 18 men with high-grade PIN underwent a repeat 
prostate biopsy. The prostate biopsy specimens showed significantly less high-grade PIN 
than historical controls. This trial provided the proof-of-concept support behind a currently 
open 485 patient placebo controlled, randomized dose finding phase IIb/III clinical trial 
(Kellof, 1997). 
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(Price et al., 2006). This trial is investigating the efficacy of toremifene in reducing prostate 
cancer incidence in men with high-grade PIN. Men with high-grade PIN are treated for 12 
months with placebo or toremifene and will undergo a repeat prostate biopsy at 6 and 12 
months (the trial details are available at http://www.gtxinc.com/tech/clinical.htm). In 
addition, the National Cancer Institute is evaluating the effects of toremifene versus placebo 
in men with prostate cancer prior to radical prostatectomy. The objective of this phase II 
clinical trial is to evaluate the effects of a toremifene on biomarkers of prostate cancer. The 
trial details are available at http://www.cancer.gov/search/ViewClinicalTrials.  
Difluoromethyl ornithine (DFMO) 
DFMO is an irreversible inhibitor of ornithine decarcoxylase involved in the synthesis of 
polyamines; it possesses cytostatic and cytotoxic effects (Messing et al., 1999). At the clinical 
level, interest in exploring DFMO as a chemoprevention agent for prostate cancer has 
recently increased as the administration of DFMO at 0.5 g/m2 daily for 4 weeks to men 
scheduled for surgical interventions to treat either prostatic hyperplasia or neoplasia 
resulted in reduction of polyamine pools, including spermine (Simoneau et al., 2001). These 
results confirm that DFMO reaches the target tissue and hence may warrant further study as 
a possible chemopreventive agent for prostate cancer.  
Selective COX-2 inhibitors 
Inhibition of COX-2 expression blocks its pro-inflammatory effects, reduces expression of 
androgen receptors and androgen inducible genes and promotes apoptosis in prostate 
cancer cells. Selective COX-2 expression has been observed in high-grade PIN, a putative 
precursor of prostate cancer, suggesting a role early in carcinogenesis (Hussain et al., 2003). 
These results support the hypothesis that inhibition of COX-2 may be an effective 
preventive strategy for prostate cancers; however, an industry-sponsored large-scale trial of 
rofecoxib was closed after the drug was withdrawn from the market because of concerns 
over its cardiovascular safety. 
Selenium 
Many of the cellular processes and molecular markers shown to be modified by selenium 
play key roles in prostate cancer progression. Two clinical trials are examining the role of 
selenium in other groups of high-risk individuals: men who have had negative prostate 
biopsies and men with HGPIN. The Negative Biopsy study, which includes men who have 
had at least one negative sextant prostate biopsy, will be using selenium supplementation in 
the form of selenium yeast, SeY (200 or 400 µg) (Marshall, 2001). The high-grade PIN study 
will determine the incidence of prostate cancer in men with biopsy-proven high grade 
intraepithelial neoplasia supplemented daily with 200 µg selenomethionine (Marshall, 2001). 
The results of these studies will be critical in defining a role for intervention with selenium 
in high-risk individuals, for whom there is no current treatment. 
Bicalutamide 
Intermittent (weekly), low-dose bicalutamide on prostate morphology revealed a tendency 
to a favorable modulation of high-risk proliferative lesions such as HGPIN. Namely, HGPIN 
status improved in 26% of treated subjects as compared with 4% of subjects in the no-
treatment arm. These findings must be interpreted with extreme caution due to the inherent 
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limitations of prostate sampling with needle biopsy. However, our analysis including all 
changes in HGPIN status (i.e., both HGPIN resolution and HGPIN development after 6 
months of treatment) may account, at least in part, for sampling errors, supporting the 
worth of our findings although they derive from a post hoc analysis. The 28% incidence of 
HGPIN found in our study was unusually high compared with that reported in the general 
population, which ranges from 0.7% to 25% in noncancerous prostate biopsies (Bubendorf et 
al., 1998). HGPIN incidence increases with age and is higher in men seen in clinical practice 
compared with men participating in screening programs (Bostwick and Qian, 2004). As 
most subjects in our study were in their seventies and as all were urological practice 
outpatients, this could partly explain our findings. Moreover, whereas HGPIN by itself does 
not seem to increase PSA (Bostwick and Qian, 2004), the incidence of HGPIN in 
homogeneous cohorts of men with elevated PSA is largely unknown. Once-a-week 
administration of bicalutamide in men at risk for prostate cancer is feasible and reasonably 
safe. This finding, coupled with the encouraging signal of activity emerging from the 
analysis of HG-PIN changes, supports further studies of this schedule at the lowest dose for 
prostate cancer prevention in men at high risk despite the negative primary end-point 
findings on Ki-67 (Zandari et al., 2009). 
Nutraceuticals and Micronutrients 
Nutraceutical compounds most commonly show antioxidant properties combined with 
other anti-neoplastic actions (Syed et al., 2008). Table 3 presents the most notable 
nutraceutical compounds examined in prostate cancer prevention, including vitamin D, 
vitamin E, selenium, lycopene, soy, and green tea (Trottier et al., 2010a & b).  
 
 
 
 
 
Table 3. Primary prostate cancer prevention with selected nutraceutical (Trottier et al., 2010) 
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9. Signal anomalies of human prostate cancer 
Prostatic intraepithelial neoplasia (PIN) lesions could be described as low grade (LG) or 
high grade (HG) and it is widely perceived that HGPIN is a precursor of prostatic 
adenocarcinoma (Isaacs et al., 2002). Since the initial growth of prostate tumor or cancer is 
dependent on androgens, hormone therapy in the form of medical or surgical castration 
constitutes a common approach for systemic treatment. However over a period of time, 
most cancer will develop androgen-independence, thereby making the continued androgen 
deprivation therapy ineffective (Taplin and Balk, 2004). While the mechanisms that drive the 
genesis of subclinical, microscopic PIN lesions, their progression to invasive cancer and 
androgen independence remain largely unknown and evidence collected in recent years 
point to certain molecular aberrations that pave the path of disease progression. 
For example, anomalies in specific  signaling molecules, including extracellular growth 
factors, protein tyrosine kinase cell surface receptors, intracellular transcription factors, 
nuclear factors and their ligands, growth suppressors, cell cycle regulators and others have 
indicated in some prostate carcinomas (Abate Shen and Shen, 2000; Gao and Isaacs, 2000; 
Roy-Burman et al., 2004) 
There is currently a strong focus on the genetic alterations or aberrations in gene expression 
that are frequently encountered in human prostate cancer in the design of mouse models. 
Although both men and mice harbour functionally equivalent prostate glands, there are 
similarities as well as differences in the anatomy and histology of the prostate in the two 
species. Similar epithelial cell types namely secretory, basal and neuroendocrine are found 
in both mouse and human prostate, although their proportions vary. While human prostate 
has a robust fibromuscular stroma, the mouse contains a modest stromal component. 
Anatomically the human prostate gland is a single, alobular structure with central, 
peripheral and transitional zones. In contrast, the mouse prostate is composed of four paired 
lobes namely anterior (AP), dorsal (DP), lateral (LP) and ventral (VP) prostate. Since DP and 
LP share a ductal system they are often dissected together and referred to as the dorsolateral 
prostate (DLP). The mouse DLP is perceived to be the most similar to the human peripheral 
zone in which the majority of clinically diagnosed prostate cancers are found. The mouse VP 
does not appear to have a human homologue and the human transitional zone does not 
have a murine homologue. The transitional zone constitutes a site where human nodular 
hyperplasia (BPH) is commonly seen. The mouse AP is analogous to the human central 
zone, which only infrequently represents a site of neoplasia in humans (Roy-Burman et al., 
2004). 
10. Cell surface signaling molecules 
Signaling interactions between various extracellular growth factors and the corresponding 
cell surface receptors converge to determine the fate of the cell with respect to proliferation, 
survival or death. In this context, dysregulation of several growth factors or their receptors 
has been implicated in prostate tumorigenesis. A number of transgenic mouse lines have 
been produced in which genes that are known to be overexpressed in human prostate 
cancer are targets. The survival factor, insulin like growth factor-I (IGF-I) which is generally 
overexpressed in human prostate and which may potentially be a good tumor marker in 
www.intechopen.com
 
Intraepithelial Neoplasia 
 
192 
prostate cancer was a target in a transgenic line (Woodson et al., 2003). Its expression  in the 
mouse tissues was designed by using the bovine keratin 5 promoter (Di Giovanni et al., 
2000). These mice develop squamous papillomas some of which progress to carcinomas of 
the skin. The increased IGF I levels also lead to pathologic changes in the prostate and in 
other male accessory glands of these animals (Di Giovanni et al., 2000a).The severity of the 
lesions in the prostate ranges from PIN to carcinoma in Situ as well as tumors with 
neuroendocrine differentiation. 
11. Fibroblast Growth Factors (FGFs) 
The FGF family of heparin binding proteins is intercellular signaling molecules of which 
atleast 23 different members (FGF-1 – FGF-23) have been identified to date. FGF proteins 
are generally secreted and their effects are mediated by a complex system of FGF receptor 
(FGFR) tyrosine kinases, either through autocrine or paracrine mechanisms, or both 
(Wilkie et al., 1995; McKeehan et al., 1998). While dysregulation of several FGFs has been 
described in prostate development and tumorigenesis, two members, FGF 7 and FGF 8 
have been further pursued through mouse modeling experiments (Djakiew, 2000; 
Thomson, 2001).  
FGF 8b has been demonstrated to possess the most transforming and tumorigenic potential 
(Daphna-Iken et al., 1998). While expression of FGF 8b appears to represent the primary 
species in prostatic epithelium, its expression is practically undetected in the stromal 
component of prostate cancer (Valve et al., 2001). Increased expression of FGF 8b in prostatic 
lesions beginning from PIN to adenocarcinoma and its persistence in androgen independent 
disease has been described. The overexpression of FGF8b in prostate cancer cells has been 
shown to increase proliferative and invasive properties of the affected cells directly and 
proliferation of prostatic stromal cells indirectly (Song et al., 2000). Consistent with these 
results antisense down regulation of FGF8b mRNA reduces the growth rate, inhibits 
cologenic activity and decreases in vivo tumorigenicity of prostate tumor cells (Rudra-
Ganguly et al., 1998). FGF 8 expressions in prostate cancer is regulated by the androgen 
receptor at the transcriptional level and that FGF 8 is angiogenic   further enhance the 
biological relevance of the factor in prostate cancer. 
Prostatic hyperplasia appears in the LP and VP in some FGF 8b transgenic animals as early 
as 2 to 3 months and in DP and AP between 6 to 16 months. LGPIN lesions manifest from 5 
to 7 months. 100% of the mice display multifocal prostatic epithelial hyperplasia during the 
first 14 months with 35% also having areas of LGPIN. In subsequent months (15 to 24 
months) the profile changes to a higher incidence of LGPIN (66%) along with HGPIN (51%). 
Ocassionally HGPIN lesions resemble the histopathology of human prostatic carcinoma in 
situ. 
12. P27kip, regulator of cyclin-cdk activity 
Activation of AKT through deregulated phosphatidylinositol 3- kinase (PI3K) signaling 
resulting from genetic inactivation of phosphatase and tensin homolog (PTEN), mutational 
activation of PI3K, or the activation of upstream oncogenic tyrosine kinases is a frequent 
molecular event in human cancer (Brugge et al., 2007; Lee et al., 2007). Transgenic expression 
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of activated AKT1 in the murine prostate induces prostatic intraepithelial neoplasia (PIN) 
that does not progress to invasive prostate cancer. In human epithelial cancers, reduced 
levels of p27Kip1 expression are frequently observed (Slingerland and Pagano, 2000) and are 
correlated with tumor progression and poor survival (Loda et al., 1997; Porter et al., 1997; 
Yang et al., 1998). p27Kip1 functions primarily as a negative regulator of cyclin-CDK activity 
and thus likely participates in tumor suppression by inhibiting cell-cycle progression (Chu 
et al., 2008). Targeted disruption of p27Kip1 (Cdkn1b_/_) in mice leads to prostatic hyperplasia 
(Cordon-Cardo et al., 1998) and development of pituitary adenomas (Fero et al., 1996, 1998) 
as the mice age. However, Cdkn1b_/_ mice do not typically develop other spontaneous 
tumors (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996). 
In many human cancer cells, oncogene-induced senescence (OIS) is associated with known 
tumor suppressor pathways such as p53, VHL, and Rb (Serrano et al., 1997; Young et al., 
2008). It has been reported that OIS occurs in many human and mouse precursors of cancer 
and that this phenomenon can be reversed by the inactivation of tumor suppressor 
pathways (Braig et al., 2005; Chen et al., 2005;  Collado et al., 2005; Michaloglou et al., 2005). 
Majumder et al. investigated the role of p27Kip1 in tumor suppression in prostate cancer 
using both genetically engineered mice and human prostate samples (Majumder et al., 2008). 
They have identified a relationship among senescence induction, p27Kip1 expression, and 
PIN that supports the notion that p27Kip1 induction in the context of early neoplastic lesions 
may represent a preinvasive checkpoint linked to cellular senescence.  
Importantly, is study is highly relevant to human prostate cancer (Majumder et al., 2008). 
Indeed, we show that p27Kip1 is overexpressed in human PIN not associated with invasive 
cancer, presumably representing the earliest phase of neoplastic transformation. In contrast, 
PIN adjacent to invasive cancer, where checkpoint loss may have already occurred, is 
associated with low levels of p27Kip1. The role of p27Kip1 in this process is further supported 
by a body of data showing that loss of p27Kip1 is commonly found in human cancers (Chu et 
al., 2008) and that invasive tumor cells specifically degrade p27Kip1. This in turn results in 
increased CDK2 activity (Loda et al., 1997).  
As many as 30% of men with a diagnosis of PIN on biopsy are subsequently found to harbor 
an invasive prostatic adenocarcinoma on repeat biopsy (Gokden et al., 2005). Thus the CDK 
inhibitors might have utility in preventing cancer progression from in situ dysplasia to 
invasion. 
13. Conclusions 
High-grade PIN is the most likely precursor of prostatic adenocarcinoma, according to 
virtually all available evidence. PIN is associated with progressive abnormalities of 
phenotype and genotype that are intermediate between normal prostatic epithelium and 
cancer, indicating impairment of cell differentiation and regulatory control with advancing 
stages of prostatic carcinogenesis. There is progressive loss of some markers of secretory 
differentiation, whereas other markers show progressive increase. The clinical importance of 
recognizing PIN is based on its strong association with prostatic carcinoma. PIN has a high 
predictive value as a marker for adenocarcinoma, and its identification in biopsy specimens 
of the prostate warrants further search for concurrent invasive carcinoma. Studies to date 
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have not determined whether PIN remains stable, regresses, or progresses, although the 
implication is that it can progress. Chemoprevention of early stage of prostate cancer, PIN 
may be useful strategy in the prostate cancer prevention. 
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